Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4- (phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions

Journal of Medicinal Chemistry

Volumn 43, Issue 7, 2000, Pages 1380-1397

  Smaill, Jeff B ^a   Rewcastle, Gordon W ^a   Loo, Joseph A ^b   Greis, Kenneth D ^c   Chan, O Helen ^b   Reyner, Eric L ^b   Lipka, Elke ^b   Showalter, H D Hollis ^b   Vincent, Patrick W ^b   Elliott, William L ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b PFIZER INC   (United States)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOPHOSPHORYLATION; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; MALIGNANT NEOPLASTIC DISEASE; MASS SPECTROMETRY; MOUSE; NONHUMAN;

ACRYLAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MICE; MICE, NUDE; MORPHOLINES; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PYRIMIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034611617     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990482t     Document Type: Article

References (36)

1. Kersemaekers, A. M. F.; Fleuren, G. J.; Kenter, E. G.; Van den Broek, L. J. C. M.; Uljee, S. M.; Hermans, J.; Van de Vijver, M. J. Oncogene alterations in carcinomas of the uterine cervix: Overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin. Cancer Res. 1999, 5, 577-586.
2. Maurizi, M.; Almadori, G.; Ferrandina, G.; Distefano, M.; Romanini, M. E.; Cadoni, G.; Benedetti-Panici, P.; Paludetti, G.; Scambia, G.; Mancuso S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer 1996, 74, 1253-1257.
3. Klohs, W. D.; Fry, D. W.; Kraker, A. J. Inhibitors of tyrosine kinase. Curr. Opin. Oncol. 1997, 9, 562-568.
4. Voldborg, B. R.; Damstrup, L.; Spang-Thomsen, M.; Poulsen, H. S. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. 1997, 8, 1197-1206.
5. Kelloff, G. J.; Fay, J. R.; Steele, V. E.; Lubet, R. A.; Boone, C. W.; Crowell, J. A.; Sigman, C. C. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prevention 1996, 5, 657-666.
6. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 7. 7-Amino-4-(phenylamino)-and 7-amino-4-[(phenylmethyl)amino]pyrido[4,3-d]-pyrimidines; a new class of inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3780-3788.
7. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; McMichael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 8. An unusually steep structure - activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 267-276.
8. Wakeling, A. E.; Barker, A. J.; Davies, D. H.; Brown, D. S.; Green, L. R.; Cartlidge, S. A.; Woodburn, J. R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 1996, 38, 67-73.
9. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhou, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine Kinase Inhibitors. 10. Isomeric 4-[(3-bromophenyl)-amino]pyrido[d]pyrimdines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 1823-1835.
10. Fry, D. W.; Nelson, J. M.; Slintak, V.; Keller, P. R.; Rewcastle, G. W.; Denny, W. A.; Zhou, H.; Bridges, A. J. Biochemical and antiproliferative properties of 4-[ar(alkyl)amino]-pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor. Biochem. Pharmacol. 1997, 54, 877-887.
11. Woodburn, J. R.; Barker, A. J.; Gibson, K. H.; Ashton, S. E.; Wakeling, A. E.; Curry, B, J.; Scarlett, L.; Henthorn, L. R. ZD 1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical trial development. Proc. Am. Assoc. Cancer Res. 1997, 38, 633 (Abstract 4251).
12. Moyer, J. D.; Barbacci, E. G.; Iwata, K. K.; Arnold, L.; Boman, B.; Cunningham, A.; DiOrio, C.; Doti, J.; Morin, M. J.; Moyer, M. P.; Neveu, M.; Pollack, V. A.; Pustilnik, L. R.; Reynolds, M. M.; Sloane, D.; Theleman, A.; Miller, P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57, 4838-4848.
13. Fry, D. W.; Bridges, A. J.; Denny, W. A.; Doherty, A.; Gries, K. D.; Hicks, J. L.; Hook, K. E.; Keller, P. R.; Leopold, W. R.; Loo, J. A.; McNamara, D, J.; Nelson, J. M.; Sherwood, V.; Smaill, J. B.; Trumpp-Kallmeyer, S.; Dobrusin, E. M. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 12022-12027.
14. Smaill, J. B.; Palmer, B. D.; Rewcastle, G. W.; Denny, W. A.; McNamara, D. J.; Dobrusin, E. M.; Bridges, A. J.; Zhou, H.; Showalter, H. D. H.; Winters, R. T.; Leopold, W. R.; Fry, D. W.; Nelson, J. M.; Slintak, V.; Elliot, W. L.; Roberts, B. J.; Vincent, P. W.; Patmore, S. J. Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J. Med. Chem. 1999, 42, 1803-1815.
15. Sherwood, V.; Bridges, A. J.; Denny, W. A.; Rewcastle, G. W.; Smaill, J. B.; Fry, D. W. Selective inhibition of heregulin-dependent tyrosine phosphorylation and cellular signaling through erbB2, erbB3 and erbB4 by PD 158780 and a new irreversible inhibitor, PD 183805. Proc: Am. Assoc. Cancer Res. 1999, 40, 723 (Abstract 4778).
16. Gogolimska, B.; Gruda, I. Synthesis of bromonitrobenzyl bromides. Acta Polon. Pharm. 1963, 20, 345-346; Chem. Abstr. 1963, 62, 463.
17. Gogolimska, B.; Gruda, I. Synthesis of bromonitrobenzyl bromides. Acta Polon. Pharm. 1963, 20, 345-346; Chem. Abstr. 1963, 62, 463.
18. Morley, J. S.; Simpson, J. C. E. The chemistry of simple heterocyclic systems. Part 1. Reactions of 6-and 7-nitro-4-hydroxyquinazoline and their derivatives. J. Chem. Soc. 1948, 360-366.
19. Barraclough, P.; Black, J. W.; Cambridge, D.; Collard, D.; Firmin, D.; Gerskowitch, V. P.; Glen, R. C.; Giles, H.; Hill, A. P.; Hull, R. A. D.; Iyer, R.; King, W. R.; Kneen, C. O.; Lindon, J. C.; Nobbs, M. S.; Randall, P.; Shah, G. P.; Smith, S.; Vine, S. J.; Whiting, M. V.; Williams, J. M. Inotropic "A" ring substituted sulmazole and isomazole analogues. J. Med. Chem. 1990, 33, 2231-2239.
20. Roth, G. A.; Tai, J. J. A new synthesis of aryl substituted quinazolin-4(1H)-ones. J. Heterocycl. Chem. 1996, 33, 2051-2053.
21. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo-and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding. J. Med. Chem. 1997, 40, 1519-1529.
22. Thompson, A. M.; Murray, D. K.; Elliott, W. L.; Fry, D. W.; Nelson, J. A.; Showalter, H. D. H.; Roberts, B. J.; Vincent, P. W.; Denny, W. A. Tyrosine kinase inhibitors. 13. Structure -activity relationships for soluble 7-substituted 4-[(3-bromophenyl)amino]-pyrido[4,3-d]pyrimidines designed as inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1997, 40, 3915-3925.
23. Trinka, U.; Buchdunger, E.; Furet, P.; Kump, W.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Rihs, G.; Lydon. N.; Traxler, P. Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J. Med. Chem. 1994, 37, 1015-1027.
24. Fenn, J. B.; Mann, M.; Meng, C. K.; Wong, S. F.; Whitehouse, C. M. Electrospray ionization for mass spectrometry of large biomoleculos. Science 1989, 246, 64-71.
25. Stewart, B. H.; Chan, O. H.; Lu, R. H.; Reyner, E. L.; Schmid, H. L.; Hamilton, H. W.; Steinbaugh, B. A.; Taylor, M. D. Comparison of intestinal permeabilities determined in multiple in vitro and in situ models; relationship to absorption in humans. Pharm. Res. 1995, 12, 693-699.
26. Scala, S.; Akhmed, N.; Rao, U. S.; Paull, K.; Lan, L. B.; Dickstein, B.; Lee, J. S.; Elgemeie, G. H.; Stein, W. D.; Bates, S. E. P-Glycoprotein substrates and antagonists cluster into two distinct groups. Mol. Pharmacol. 1997, 51, 1024-1033.
27. Horio, M.; Lovelace, E.; Pastan, I.; Gottesman, M. M. Agents which reverse multidrug-resistance are inhibitors of [3H]vinblastine transport by isolated vesicles. Biochim. Biophys. Acta 1991, 1061, 106-111.
28. Zacherl, J.; Hamilton, G.; Thalhammer, T.; Riegler, M.; Cosentini, E. P.; Ellinger, A.; Bischof, G.; Schweitzer, M.; Teleky, B.; Koperna, T.; Wenzl, E. Inhibition of P-glycoprotein-mediated vinblastine transport across HCT-8 intestinal carcinoma monolayers by verapamil, cyclosporine A and SDZ PSC 833 in dependence on extracellular pH. Cancer Chemother. Pharmacol. 1994, 34, 125-132.
29. Ford, J. M.; Hait, W. M. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev. 1990, 42, 155-199.
30. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson. J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors, 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J. Med. Chem. 1996, 39, 918-928.
31. Meier, J. Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agents. Am. Heart J. 1982, 104, 364-373.
32. Fagerholm, U.; Johansson, M.; Lennernas, H. Comparison between permeability coefficients in rat and human jejunum. Pharm. Res. 1996, 13, 1336-1342.
33. Schabel, F. M., Jr.; Griswold, D. P., Jr.; Laster, W. R., Jr.; Corbett, T. H.; Lloyd, H. H. Quantitative evaluation of anticancer agent activity in experimental animals. Pharmacol. Ther. 1977, 1, 411-435.
34. Leopold, W. R.; Nelson, J. M.; Plowman, J.; Jackson, R. C. Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res. 1985, 45, 5532-5539.
35. Elliott, W. L.; Howard, C. T.; Dykes, D. J.; Leopold, W. R. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice. Cancer Res. 1989, 49, 5586-5590.
36. Elliott, W. L.; Roberts, B. J.; Howard, C. T.; Leopold, W. R. Chemotherapy with [SP-4-3-(R )]-[1,1-cyclobutanedicarboxylato-(2-)](2-methyl-1,4-butanediamine-N,N′) platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo. Cancer Res. 1994, 54, 4412-4418.